Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):56-61. doi: 10.1016/j.bbmt.2012.08.003. Epub 2012 Aug 11.

2.

Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.

Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J, Ratanatharathorn V, Uberti J.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1455-61. doi: 10.1016/j.bbmt.2012.03.010. Epub 2012 Mar 24.

3.

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.

Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT.

Bone Marrow Transplant. 2013 Jul;48(7):966-71. doi: 10.1038/bmt.2012.257. Epub 2012 Dec 17.

PMID:
23241739
4.

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2100-2105. doi: 10.1016/j.bbmt.2015.08.026. Epub 2015 Aug 29.

5.

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.

Bone Marrow Transplant. 2006 Oct;38(7):501-6.

PMID:
16980998
6.

Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.

Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallón L, Ribera JM.

Eur J Haematol. 2014 Dec;93(6):487-91. doi: 10.1111/ejh.12386. Epub 2014 Jun 21.

PMID:
24889275
7.

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.

Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N, Safaian N, Kondakci M, Saure C, Germing U, Haas R, Fenk R.

Ann Oncol. 2010 Sep;21(9):1898-904. doi: 10.1093/annonc/mdq059. Epub 2010 Mar 16.

PMID:
20233744
8.

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S; European Blood and Marrow Transplantation Mucositis Advisory Group.

J Clin Oncol. 2008 Mar 20;26(9):1519-25. doi: 10.1200/JCO.2007.13.6028. Epub 2008 Feb 11.

PMID:
18268357
9.

Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.

Lucchese A, Matarese G, Manuelli M, Ciuffreda C, Bassani L, Isola G, Cordasco G, Gherlone E.

Minerva Stomatol. 2016 Feb;65(1):43-50.

PMID:
26862696
10.

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74. doi: 10.1016/j.bbmt.2012.08.009. Epub 2012 Aug 13.

11.
12.

Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.

Chen J, Seabrook J, Fulford A, Rajakumar I.

J Oncol Pharm Pract. 2017 Mar;23(2):116-120. doi: 10.1177/1078155215620920. Epub 2016 Jul 9.

PMID:
26684614
13.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

14.

Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.

Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS.

Ann Intern Med. 2010 Sep 21;153(6):358-67. doi: 10.7326/0003-4819-153-6-201009210-00003.

PMID:
20855800
15.

Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA.

Cancer Invest. 2011 Mar;29(3):214-9. doi: 10.3109/07357907.2010.550663.

PMID:
21314330
16.

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.

Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K; Australasian Leukemia and Lymphoma Group.

Bone Marrow Transplant. 2005 May;35(10):971-7.

PMID:
15778725
17.

Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.

Lucchese A, Matarese G, Ghislanzoni LH, Gastaldi G, Manuelli M, Gherlone E.

Leuk Lymphoma. 2016;57(4):820-7. doi: 10.3109/10428194.2015.1081192. Epub 2015 Nov 20.

PMID:
26428409
18.

High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.

Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, Scalone R, Pinto A, Martino M.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1932-8. doi: 10.1016/j.bbmt.2015.06.011. Epub 2015 Jun 19.

19.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.

Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T.

Bone Marrow Transplant. 2014 Jun;49(6):761-6. doi: 10.1038/bmt.2014.56. Epub 2014 Mar 24.

PMID:
24662419
20.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

Supplemental Content

Support Center